Patent Number: 6,254,868

Title: Glycosylated humanized B-cell specific antibodies

Abstract: A humanized specific monoclonal antibody or antibody fragment, especially a B-cell specific antibody or antibody fragment, is engineered to contain a glyxosylation site in the non-Fc constant region. The glycosylated antibody is useful for diagnosis and/or therapy whenever a targeting antibody or fragment is used, especially for B-cell malignancies. The carbohydrate moiety allows conjugation of labeling or therapeutic agents of increased size, without affecting the binding affinity or specificity of the antibody.

Inventors: Leung; Shui-on (Madison, NJ), Hansen; Hans (Mystic Island, NJ), Qu; Zhengxing (Warren, NJ)

Assignee: Immunomedics, Inc.

International Classification: C07K 16/18 (20060101); C07K 16/28 (20060101); A61K 38/00 (20060101); A61K 039/395 ()

Expiration Date: 07/03/2018